Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
Janus kinase inhibitors, also known as JAK inhibitors, JAKinibs or JAKi, are a new group of disease-modifying drugs. They work by inhibiting enzymes involved in the transmission of information from receptors located in the cell membrane to the cell interior, specifically to the cell nucleus, thus di...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-12-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/28/24/8064 |
| _version_ | 1797379956098990080 |
|---|---|
| author | Izabella Ryguła Wojciech Pikiewicz Konrad Kaminiów |
| author_facet | Izabella Ryguła Wojciech Pikiewicz Konrad Kaminiów |
| author_sort | Izabella Ryguła |
| collection | DOAJ |
| description | Janus kinase inhibitors, also known as JAK inhibitors, JAKinibs or JAKi, are a new group of disease-modifying drugs. They work by inhibiting enzymes involved in the transmission of information from receptors located in the cell membrane to the cell interior, specifically to the cell nucleus, thus disrupting the JAK-STAT pathway. This pathway plays a role in key cellular processes such as the immune response and cell growth. This feature is used in the treatment of patients with rheumatological, gastroenterological and hematological diseases. Recently, it has been discovered that JAK-STAT pathway inhibitors also show therapeutic potential against dermatological diseases such as atopic dermatitis, psoriasis, alopecia areata and acquired vitiligo. Studies are underway to use them in the treatment of several other dermatoses. Janus kinase inhibitors represent a promising class of drugs for the treatment of skin diseases refractory to conventional therapy. The purpose of this review is to summarize the latest knowledge on the use of JAKi in dermatological treatment. |
| first_indexed | 2024-03-08T20:30:32Z |
| format | Article |
| id | doaj.art-fe384e514fac40f996d071b994601627 |
| institution | Directory Open Access Journal |
| issn | 1420-3049 |
| language | English |
| last_indexed | 2024-03-08T20:30:32Z |
| publishDate | 2023-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Molecules |
| spelling | doaj.art-fe384e514fac40f996d071b9946016272023-12-22T14:27:36ZengMDPI AGMolecules1420-30492023-12-012824806410.3390/molecules28248064Novel Janus Kinase Inhibitors in the Treatment of Dermatologic ConditionsIzabella Ryguła0Wojciech Pikiewicz1Konrad Kaminiów2Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-752 Katowice, PolandDepartment of Medical and Health Sciences, Collegium Medicum—Faculty of Medicine, WSB University, 41-300 Dąbrowa Górnicza, PolandDepartment of Medical and Health Sciences, Collegium Medicum—Faculty of Medicine, WSB University, 41-300 Dąbrowa Górnicza, PolandJanus kinase inhibitors, also known as JAK inhibitors, JAKinibs or JAKi, are a new group of disease-modifying drugs. They work by inhibiting enzymes involved in the transmission of information from receptors located in the cell membrane to the cell interior, specifically to the cell nucleus, thus disrupting the JAK-STAT pathway. This pathway plays a role in key cellular processes such as the immune response and cell growth. This feature is used in the treatment of patients with rheumatological, gastroenterological and hematological diseases. Recently, it has been discovered that JAK-STAT pathway inhibitors also show therapeutic potential against dermatological diseases such as atopic dermatitis, psoriasis, alopecia areata and acquired vitiligo. Studies are underway to use them in the treatment of several other dermatoses. Janus kinase inhibitors represent a promising class of drugs for the treatment of skin diseases refractory to conventional therapy. The purpose of this review is to summarize the latest knowledge on the use of JAKi in dermatological treatment.https://www.mdpi.com/1420-3049/28/24/8064JAK inhibitorsJanus kinase inhibitorsJAKinibsJAK-STAT pathwayautoimmune skin diseasesinflammatory skin conditions |
| spellingShingle | Izabella Ryguła Wojciech Pikiewicz Konrad Kaminiów Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions Molecules JAK inhibitors Janus kinase inhibitors JAKinibs JAK-STAT pathway autoimmune skin diseases inflammatory skin conditions |
| title | Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions |
| title_full | Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions |
| title_fullStr | Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions |
| title_full_unstemmed | Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions |
| title_short | Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions |
| title_sort | novel janus kinase inhibitors in the treatment of dermatologic conditions |
| topic | JAK inhibitors Janus kinase inhibitors JAKinibs JAK-STAT pathway autoimmune skin diseases inflammatory skin conditions |
| url | https://www.mdpi.com/1420-3049/28/24/8064 |
| work_keys_str_mv | AT izabellaryguła noveljanuskinaseinhibitorsinthetreatmentofdermatologicconditions AT wojciechpikiewicz noveljanuskinaseinhibitorsinthetreatmentofdermatologicconditions AT konradkaminiow noveljanuskinaseinhibitorsinthetreatmentofdermatologicconditions |